Haploidentical hematopoietic cell transplantation

Bone Marrow Transplantation

Volumn 42, Issue SUPPL.1, 2008, Pages

  Koh, L P ^a   Chao, N ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; LYMPHOCYTE ANTIBODY; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; SIPLIZUMAB; TACROLIMUS; THIOTEPA;

CELLULAR IMMUNITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; GENOTYPE; GRAFT VERSUS HOST REACTION; HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNITY; INFECTION; LYMPHOCYTE DEPLETION; MORBIDITY; MORTALITY; NEUROTOXICITY; NONMYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REVIEW; RISK ASSESSMENT; SIBLING; T LYMPHOCYTE; WHOLE BODY RADIATION;

GRAFT VS HOST DISEASE; HAPLOTYPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS;

EID: 50549094616     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.117     Document Type: Review

References (30)

1. Confer DL. Unrelated marrow donor registries. Curr Opin Hematol 1997; 4: 408-412.
2. Beatty PG, Mori M, Milford E. Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor. Transplantation 1995; 60: 778-783.
3. Hansen JA, Petersdorf E, Martin PJ, Anasetti C. Hematopoietic stem cell transplants from unrelated donors. Immunol Rev 1997; 157: 141-151.
4. Howe CWS, Radde-Stepaniak T. Hematopoietic cell donor registrice In: Thomas ED, Blume KG, Forman SJ (eds). Hematopoietic Cell Transplantation, 2nd edn. Blackwell Science: Malden, MA, 1999, pp 503-512.
5. Davies SM, Kollman C, Anasetti C, Antin JH, Gajewski J, Casper JT et al. Engraftment and survival after unrelated-donor bone marrow transplantation: A report from the national marrow donor program. Blood 2000; 96; 4096-4102.
6. McGlave PB, Shu XO, Wen W, Anasetti C, Nademanee A, Champlin R et al Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood 2000; 95: 2219-2225.
7. Anasetti C. Transplantation of hematopoietic stem cells from alternate donors in acute myelogenous leukemia. Leukemia 2000; 14: 502-504.
8. Sierra J, Storer B, Hansen JA, Martin PJ, Petersdorf EW, Woolfrey A et al. Unrelated donor marrow transplantation for acute myeloid leukemia: An update of the Seattle experience. Bone Marrow Transplant 2000; 26: 397-404.
9. Aversa F, Velardi A, Tabilio A, Reisner Y, Martelli MF. Haploidentical stem cell transplantation in leukemia. Blood Rev 2001; 15: 111-119.
10. Rocha V, Wagner Jr JE, Sobocinkski KA, Klein JP, Zhang MJ, Horowitz MM et al. Graft-versus-host disease in children who have received a cord blood or bone marrow transplant from an HLA-identical sibling. N Engl J Med 2000; 342: 1846-1854.
11. Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 2001; 344: 1815-1822.
12. Long GD, Laughlin M, Madan B, Kurtzberg J, Gasparetto C, Morris A et al. Unrelated umbilical cord blood transplantation in adult patients. Biol Blood Marrow Transplant 2003; 9: 772-780.
13. Lang P, Bader P, Schumm M, Feuchtinger T, Einsele H, Führer M et al. Transplantation of a combination of CD133 + and CD34 + selected progenitor cells from alternative donors. Br J Haematol 2004; 124: 72-79.
14. Kawano Y, Takaue Y, Watanabe A, Takeda O, Arai K, Itoh E et al. Partially mismatched pediatric transplants with allogeneic CD34(+) blood cells from a related donor. Blood 1998; 92: 3123-3130.
15. Peters C, Matthes-Martin S, Fritsch G, Holter W, Lion T, Witt V et al Transplantation of highly purified peripheral blood CD34 + cells from HLA-mismatched parental donors in 14 children: Evaluation of early monitoring of engraftment. Leukemia 1999; 13: 2070-2078.
16. Passweg JR, Kuhne T, M Gregor M, Favre G, Avoledo P, Tichelli A et al Increased stem cell dose, as obtained using currently available technology, may not be sufficient for engraftment of haploidentical stem cell transplants. Bone Marrow Transplantation 2000; 26: 1033-1036.
17. Henslee-Downey PJ. Allogeneic transplantation across major HLA barriers. Best Pract Res Clin Haematol 2001; 14: 741-754.
18. Rizzieri DA, Koh LP, Long GD, Gasparetto C, Sullivan KM, Horwitz M et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 2007; 25: 690-697.
19. Barfield RC, Otto M, Houston J, Holladay M, Geiger T, Martin J et al A one-step large-scale method for T- and B-cell depletion of mobilized PBSC for allogeneic transplantation. Cytotherapy 2004; 6: 1-6.
20. Hale G, Kimberly K, Lovins R, Woodard J, Leung W, Yusuf U et al. CD3 Depleted hematopoietic peripheral blood stem cell grafts in children with refractory hematologic malignancies undergoing transplantation from mismatched related donors [abstract]. Blood 2005; 106: 451b.
21. Bethge WA, Haegele M, Faul C, Lang P, Schumm M, Bornhauser M et al Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: Fast engraftment and low toxicity. Exp Hematol 2006; 34: 1746-1752.
22. Handgretinger R, Chen X, Pfeiffer M, Mueller I, Feuchtinger T, Hale GA et al. Feasability and outcome of reduced intensity conditioning in haploidentical transplantation. Ann N Y Acad Sci 2007; 1106 279-289.
23. Pelot MR, Pearson DA, Swenson K, Zhao G, Sachs J, Yang YG et al. Lymphohematopoietic graft-vs-host reactions can be induced without graft-vs-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Biol Blood Marrow Transplant 1999; 5: 133-143.
24. Spitzer TR, McAfee SL, Dey BR, Colby C, Hope J, Grossberg H et al. Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies. Transplantation 2003; 75: 1448-1751.
25. Dey BR, Spitzer TR. Current status of haploidentical stem cell transplantation. Br J Haematol 2006; 135: 423-437.
26. Spitzer TR. Haploidentical stem cell transplantation: The always present but overlooked donor. Hematology Am Soc Hematol Educ Program 2005, 390-395.
27. O'Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002; 8: 377-386.
28. Ogawa H, Ikegame K, Yoshihara S. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biol Blood Marrow Transplant 2006; 12: 1073-1084.
29. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
30. Kanda Y, Oshima K, Asano-Mori Y, Kandabashi K, Nakagawa M, Sakata-Yanagimoto M et al. In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation. Transplantation 2005; 79: 1351-1357.